Navigation Links
Elixir Pharmaceuticals Announces Clinical Data at American Diabetes,Association Conference Highlighting Ability of Glufast to Maintain,Glycemic Control in Patients with Type 2 Diabetes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Elixir Pharmaceuticals, Inc., announced today the publication of clinical data highlighting the ability of Glufast(R) (mitiglinide calcium hydrate) monotherapy, or combination therapy with metformin, to manage glucose surges before and after meals. The data were published in the Abstract Book for the American Diabetes Association 67th Annual Scientific Sessions in Chicago, Illinois. Glufast is an insulin secretagogue that lowers postprandial (post-meal) glucose levels by improving the body's own ability to produce insulin. Marketed in Japan since 2004, Glufast has an extensive clinical package that demonstrates the product's ability to effectively and safely treat Type 2 diabetes.

"The publication of these data provide compelling confirmatory evidence that Glufast can control and reduce post-meal glucose, and in combination with metformin may offer complete glucose management, both before and after meals," commented William K. Heiden, Elixir's President and Chief Executive Officer. "These studies and other similar data led us to in-license Glufast, which we expect to be our first commercial product. This drug has been well received outside of the U.S., and its efficacy and safety are well documented. As endocrinologists and general practitioners have different prescribing habits and dosing requirements, we will be pursuing Glufast both as a single agent and in combination with metformin to meet their needs. We are working towards initiating a final Phase III clinical study of Glufast in the U.S. this year."

The first study detailed findings from a randomized, double-blind trial comparing Glufast to acarbose in 369 elderly patients (at least 65 years of age) with Type 2 diabetes mellitus (T2DM). The patients were randomized to receive either Glufast or acarbose and were stratified by country and prior oral hyperglycemic agent (OHA) treatment. More than 80
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)... SAN DIEGO , July 10, 2014  RESMED INC. ... report its fourth quarter and fiscal year ended June 30, ... York Stock Exchange market close. A press release with ResMed,s ... and the company will host a webcast to discuss operating ... scheduled to begin at 1:30 p.m. US Pacific Time and ...
(Date:7/10/2014)... , July 10, 2014   Ventana Medical Systems, ... announced it has entered into an agreement with Merck ... as EMD Serono in the United States ... collaborate with Merck KGaA,s biopharmaceutical division on the development ... undisclosed target using Ventana,s proprietary diagnostic assays. In alignment ...
Breaking Medicine Technology:Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2ResMed To Announce Fourth Quarter And Fiscal Year-End 2014 Results 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 2Ventana Medical Systems, Inc. and Merck KGaA, Darmstadt, Germany to develop companion diagnostic test for cancer treatment 3
(Date:7/12/2014)... July 12, 2014 In ... report, ‘cognitive assessment and training’ is defined ... assess, train, or enhance cognitive functions. These ... as in dementia screening, clinical trials, driver’s ... learning, self assessment, brain training, and employers’ ...
(Date:7/12/2014)... 12, 2014 Tylenol lawsuits ( ... move forward in the federal multidistrict litigation underway ... Bernstein Liebhard LLP reports. According to a filing ... F. Stengel has ordered the deposition of a ... found that the witness’s testimony concerning the marketing ...
(Date:7/12/2014)... 2014 "The second toes cross over the ... to wear shoes," said an inventor from East Hartford, Conn. ... this from happening. , He then created a prototype of ... the second and big toes from overlapping. This avoids discomfort ... Ergonomic and easy to use, it's ideal for people with ...
(Date:7/12/2014)... York (PRWEB) July 12, 2014 As ... move forward in U.S. courts, Bernstein Liebhard LLP notes ... metal ion levels to the failure of metal-on-metal hip ... issue of The Journal of Bone & Joint Surgery, ... unilateral Articular Surface Replacement prostheses at least twelve months ...
(Date:7/12/2014)... “Critical Care Therapeutics in Major ... Four-Factor PCCs and Recombinant Products to Drive Market,” ... market in the US, UK, France, Germany, Italy, ... estimation of market size for 2013, along with ... indications that are being treated using the five ...
Breaking Medicine News(10 mins):Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 2Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 3Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 4Health News:Global Cognitive Assessment & Training Market: 27.3% CAGR to 2018 Says a New Research Report Available at LifeScienceIndustryResearch.com 5Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 2Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 3Health News:Tylenol Lawsuit News: U.S. District Judge Overseeing Federal Tylenol Liver Damage Litigation Orders Deposition of Former McNeil President, Bernstein Liebhard LLP Reports 4Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 2Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 3Health News:DePuy Pinnacle Hip Lawsuit News: Bernstein Liebhard LLP Notes Release of New Study Tying Elevated Metal Ions to Metal-on-Metal Hip Failure 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 2Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 3Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 4Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 5Health News:Critical Care Therapeutics in Major Developed Market is Expected to Grow at a CAGR of 4.7% to $2.5 Billion in 2019 6
... arrested for mailing thousands of anthrax hoax ... mailed to US President George W Bush. ... allegedly threatened to use a weapon of ... that the letters were mailed to government ...
... Pennsylvania school of medicine have found that patients who had ... arteries in head are in the risk of developing a ... Professor Scott Kasner and researchers is to be published in ... may help in early detection of second stroke and it ...
... Indian State of Kerala fell ill and were admitted to ... // District Collector N. Ayappan said the condition of the ... and Government School at Manacuad, are stable. The district administration ... free meal scheme, and the chances of sabotage have not ...
... caused in human beings due to an excessive use ... which are useful to human beings. // This causes ... who have been undergoing treatment with antibiotics. ... life-threatening complications. But scientists say it has also begun ...
... Engineering Center (IEEC) of the Binghamton University has ... the New York State Office of Science, Technology ... of the Microelectronics Research in the roll-to-roll format. ... funding such initiatives, recognized by the New York ...
... meeting with Boston Scientific to talk about the repairs in ... held in 2001 with Schering-Plough // about problems with its ... to make any amendments. This provoked the FDA to withhold ... solve this problem Raul E. Cesan, the company's president and ...
Cached Medicine News:Health News:$ 1.7 Million NYSTAR Award for Binghamton University to Flex Electronics Research Muscle. 2
The PC4200h is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
The PC4200i is the largest capacity platelet incubator available. It features a built-in agitator with a capacity of 396 random bags (132 apheresis)....
... Platelet incubators hold rotators ... Incubator temperature can be set ... from 15C to 40C (59F ... 0.5C from top to bottom. ...
ELISA for detection of Anti-Gliadin IgA....
Medicine Products: